



# Allosteric Nanobodies Reveal the Dynamic Range and Diverse Mechanisms of GPCR Activation

The Harvard community has made this  
article openly available. [Please share](#) how  
this access benefits you. Your story matters

|                   |   |
|-------------------|---|
| Citation          | Staus, D. P., R. T. Strachan, A. Manglik, B. Pani, A. W. Kahsai, T. H. Kim, L. M. Wingler, et al. 2016. "Allosteric Nanobodies Reveal the Dynamic Range and Diverse Mechanisms of GPCR Activation." <i>Nature</i> 535 (7612): 448-452. doi:10.1038/nature18636. <a href="http://dx.doi.org/10.1038/nature18636">http://dx.doi.org/10.1038/nature18636</a> . |
| Published Version | <a href="https://doi.org/10.1038/nature18636">doi:10.1038/nature18636</a>   |
| Citable link      | <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:30370944">http://nrs.harvard.edu/urn-3:HUL.InstRepos:30370944</a>   |
| Terms of Use      | This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a>            |



Published in final edited form as:

*Nature*. 2016 July 21; 535(7612): 448–452. doi:10.1038/nature18636.

## Allosteric Nanobodies Reveal the Dynamic Range and Diverse Mechanisms of GPCR Activation

Dean P Staus<sup>1,\*</sup>, Ryan T Strachan<sup>2,\*</sup>, Aashish Manglik<sup>3,\*</sup>, Biswaranjan Pani<sup>1</sup>, Alem W Kahsai<sup>1</sup>, Tae Hun Kim<sup>4</sup>, Laura M Wingler<sup>1</sup>, Seungkirl Ahn<sup>1</sup>, Arnab Chatterjee<sup>1</sup>, Ali Masoudi<sup>1</sup>, Andrew C Kruse<sup>5</sup>, Els Pardon<sup>6,7</sup>, Jan Steyaert<sup>6,7</sup>, William I Weis<sup>3,8</sup>, R. Scott Prosser<sup>4</sup>, Brian K Kobilka<sup>3</sup>, Tommaso Costa<sup>9</sup>, and Robert J Lefkowitz<sup>1,10,11</sup>

<sup>1</sup>Department of Medicine, Duke University Medical Center, Durham, North Carolina, 27710, USA

<sup>2</sup>Department of Pharmacology, University of North Carolina, Chapel Hill, North Carolina, 27599, USA

<sup>3</sup>Department of Molecular and Cellular Physiology, Stanford University School of Medicine, California, 94305, USA

<sup>4</sup>Department of Chemistry, University of Toronto, UTM, 3359 Mississauga Road North, Mississauga, Ontario L5L 1C6, Canada

<sup>5</sup>Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, 02115, USA

<sup>6</sup>Structural Biology Brussels, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium

<sup>7</sup>Structural Biology Research Center, VIB, Pleinlaan 2, 1050 Brussels, Belgium

<sup>8</sup>Department of Structural Biology, Stanford University School of Medicine, Stanford, California, 94305, USA

<sup>9</sup>Department of Pharmacology, Istituto Superiore di Sanità, Rome, Italy

<sup>10</sup>Department of Biochemistry, Duke University Medical Center, Durham 27710, North Carolina, USA

---

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:[http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

Correspondence and requests for materials should be addressed to R.J.L. (lefko001@receptor-biol.duke.edu), B.K.K. (kobilka@stanford.edu), or T.C. (tommaso.costa@iss.it).

\*Authors contributed equally

Coordinates and structure factors for the  $\beta_2$ AR-Nb60-Carazolol complex are deposited in the Protein Data Bank (accession code 5JQH).

The authors declare no competing financial interests. Readers are welcome to comment on the online version of this article at [www.nature.com/nature](http://www.nature.com/nature).

**Author Contributions** D.P.S. and R.T.S. conceived the project. Pharmacological assessment of the interactions between Nb60 and Nb80 with the  $\beta_2$ AR were designed, performed and analyzed by D.P.S., R.T.S., B.P., S.A., and A.C. Formation, purification, and crystallization of the  $\beta_2$ AR-Nb60-Carazolol complex was conducted by D.P.S. and A.M. Data collection, refinement, and structural analysis was done by A.M., A.C.K., and A. Masoudi, and W.I.W. NMR spectroscopy was executed by A.M., T.H.K., and supervised by R.S.P. Isothermal titration calorimetry was conducted by A.W.K. Nanobody reagents were provided by E.P. and J.S. Detailed allosteric analysis of radioligand binding data was implemented by T.C. Figures were created by D.P.S., A.M., T.C., L.M.W., R.T.S., and A. Masoudi. Manuscript was written by D.P.S., T.C., R.T.S., L.M.W., A.M., A.C.K., and R.J.L. Overall research was supervised by B.K.K. and R.J.L.

<sup>11</sup>Howard Hughes Medical Institute

## Abstract

G-protein coupled receptors (GPCRs) modulate many physiological processes by transducing a variety of extracellular cues into intracellular responses. Ligand binding to an extracellular orthosteric pocket propagates conformational change to the receptor cytosolic region to promote binding and activation of downstream signaling effectors such as G proteins and  $\beta$ -arrestins. It is widely appreciated that different agonists can share the same binding pocket but evoke unique receptor conformations leading to a wide range of downstream responses (i.e., 'efficacy')<sup>1</sup>. Furthermore, mounting biophysical evidence, primarily using the  $\beta$ -adrenergic receptor ( $\beta_2$ AR) as a model system, supports the existence of multiple active and inactive conformational states<sup>2-5</sup>. However, how agonists with varying efficacy modulate these receptor states to initiate cellular responses is not well understood. Here we report stabilization of two distinct  $\beta_2$ AR conformations using single domain camelid antibodies (nanobodies): a previously described positive allosteric nanobody (Nb80) and a newly identified negative allosteric nanobody (Nb60)<sup>6,7</sup>. We show that Nb60 stabilizes a previously unappreciated low affinity receptor state which corresponds to one of two inactive receptor conformations as delineated by X-ray crystallography and NMR spectroscopy. We find that the agonist isoproterenol has a 15,000-fold higher affinity for the  $\beta_2$ AR in the presence of Nb80 compared to Nb60, highlighting the full allosteric range of a GPCR. Assessing the binding of 17 ligands of varying efficacy to the  $\beta_2$ AR in the absence and presence of Nb60 or Nb80 reveals large ligand-specific effects that can only be explained using an allosteric model which assumes equilibrium amongst at least three receptor states. Agonists generally exert efficacy by stabilizing the active Nb80-stabilized receptor state ( $R_{80}$ ). In contrast, for a number of partial agonists, both stabilization of  $R_{80}$  and destabilization of the inactive, Nb60-bound state ( $R_{60}$ ) contribute to their ability to modulate receptor activation. These data demonstrate that ligands can initiate a wide range of cellular responses by differentially stabilizing multiple receptor states.

---

The allosteric behavior of GPCRs is responsible for the complex signaling properties associated with these important regulators of human physiology. GPCR allostery, defined here as a linkage between the extracellular orthosteric ligand pocket and the intracellular G-protein binding pocket, has long been analyzed by pharmacological methods<sup>8-10</sup> (see supplemental material for additional information). Conformational changes within a GPCR induced by agonist binding can enhance the affinity and binding of intracellular signaling transducers, such as G-proteins and  $\beta$ -arrestins. Conversely, transducer coupling further enhances agonist affinity, resulting in the formation of the ternary complex of receptor, transducer, and ligand (Fig. 1a). The conceptual framework of the ternary complex model (TCM) equates the magnitude of these affinity changes with the strength of transducer activation in cells<sup>11,12</sup>, as demonstrated for several GPCR systems<sup>13-16</sup>. However, the structural basis underlying these allosteric relationships and how they relate to ligand efficacy is not well understood.

Ligand-dependent GPCR activation has traditionally been conceptualized as a conversion between a single inactive and a single active receptor state. However, recent studies utilizing various spectroscopic techniques have identified multiple inactive and active receptor states,

suggesting that the mechanisms underlying receptor activation may be more complex than previously thought<sup>2-5</sup>. To better understand how ligands with varying efficacies may differentially regulate these conformations, we sought to develop reagents to stabilize specific inactive and active conformations of the  $\beta_2$ AR. We and others have previously utilized Nb80, a Gs mimetic nanobody, to stabilize an active conformation of the  $\beta_2$ AR<sup>6,7</sup>. Indeed, competition radioligand binding assays using iodinated cyanopindolol ( $[^{125}\text{I}]\text{-CYP}$ ) and  $\beta_2$ AR reconstituted into high-density lipoprotein (HDL) particles (nanodiscs) demonstrated that Nb80 increases the affinity of the agonist isoproterenol (ISO) by 75 fold (Fig. 1b), which is similar, but not identical, to the 33 fold increase seen in the presence of purified heterotrimeric Gs (Fig. 1b). To investigate the pharmacological properties of the inactive receptor we identified a nanobody (Nb60) that preferentially bound inverse agonist-bound  $\beta_2$ AR<sup>7</sup>. Remarkably, though the affinity of the receptor for agonist in the absence of Gs or Nb80 was presumed to reflect the pharmacological properties of the inactive state, the presence of Nb60 reduced agonist affinity by approximately 70 fold (Fig. 1b). The effects of Nb60 and Nb80 on radiotracer affinity were negligible and could not account for the large changes in affinity (Extended Data Table 1).

To further quantitate the allosteric effects of Nb60 and Nb80/Gs on agonist binding, we measured ISO affinity with radioligand competition binding over a range of nanobody/Gs concentrations (Extended Data Figure 1). As the concentration of allosteric modulator increases, the effect on ISO affinity becomes saturable, reaching two opposite plateau values with Nb60 and Nb80/Gs (Fig. 1c). This is a hallmark pattern of true allosteric interactions, with the net log-change in ISO affinity at saturating concentration of nanobody/Gs gauging the extent of cooperativity between nanobody and agonist binding (negative for Nb60 or positive for Nb80/Gs) (see supplemental information). As predicted by the TCM, this coupling energy, termed  $\alpha$ , must be constant; i.e. the effect of bound nanobody on agonist binding is reciprocal to the effect of bound agonist on nanobody binding. To verify such a prediction, we measured the affinity of Nb60 for the  $\beta_2$ AR in the absence and presence of agonist (ISO) using isothermal titration calorimetry (Fig. 1d, e). As expected the affinity of Nb60 for  $\beta_2$ AR decreased in the presence of ISO. Consistent with its preference for the inactive state, Nb60 dose-dependently increased binding of the radiolabeled inverse antagonist  $[^3\text{H}]\text{-ICI-118,551}$  to the  $\beta_2$ AR, whereas binding was decreased in the presence of Nb80 (Fig. 1f). Taken together, these data show that Nb60 and Nb80 are potent allosteric modulators that can be used to stabilize inactive and active  $\beta_2$ AR states.

The decrease in ISO affinity observed in the presence of Nb60 reveals a previously unappreciated “very low affinity” state ( $K_{\text{VL}}$ ) in competition binding experiments. The affinity of agonist for an uncoupled GPCR has traditionally been referred to as the “low affinity” ( $K_{\text{L}}$ ) state; however, our results show that  $K_{\text{L}}$  values reflect binding of an ensemble of conformations that exchange rapidly over the course of the binding reaction. This phenomenon is likely conserved among GPCRs as a similar  $K_{\text{VL}}$  state has been observed with the A(2A) adenosine receptor using an antibody fragment<sup>17</sup>. This conformational heterogeneity is consistent with recent spectroscopic and computational studies, which have shown that the  $\beta_2$ AR exists in multiple inactive, intermediate, and active conformations that exchange within milliseconds<sup>2-5,18</sup>. To assess which receptor state Nb60 stabilizes, we conducted  $^{19}\text{F}$ -fluorine NMR spectroscopy of  $\beta_2$ AR labeled with a trifluoroacetanilide probe

at the endogenous residue C265 located at the cytoplasmic end of transmembrane 6 (TM6). As shown previously, the unliganded  $\beta_2$ AR exists in two equally distributed inactive states (termed S1 and S2) that exchange on a fast timescale ( $700 \pm 137 \mu\text{s}$ ), and complete conversion into the active S4 state requires both agonist and transducer binding (Fig. 2a,b)<sup>5</sup>. Using structural insights from double electron-electron resonance studies, S1 was identified as an inactive state with an interaction between TM3 residue R131<sup>3.50</sup> (superscripts indicate Ballesteros-Weinstein numbering for GPCRs<sup>19</sup>) and E268<sup>6.30</sup> in TM6<sup>5</sup>, commonly termed the ionic lock. The ionic lock has previously been shown to be important in maintaining the inactive conformation of  $\beta_2$ AR, as charge neutralizing mutations at these positions increase receptor constitutive activity<sup>20</sup>. Additionally, the S2 conformation was also identified as an inactive state but with a disengaged ionic lock (Fig 2b). The binding of G-protein or other positive allosteric modulators such as Nb80 lowers the energy of the active receptor states, driving the receptor from S2 towards active conformations<sup>5</sup>. The <sup>19</sup>F-NMR spectra showed that the addition of Nb60 to  $\beta_2$ AR bound to the inverse agonist carazolol shifted the S1–S2 equilibrium towards the inactive S2 state (Fig. 2c), providing a mechanism for its negative cooperative effects on ISO affinity. Given the broad NMR line shape (Fig. 3c, red line) of the  $\beta_2$ AR when bound to carazolol and Nb60, we conducted Carr-Purcell-Meiboom-Gill (CPMG)<sup>21</sup> relaxation dispersion measurements to measure potential conformational heterogeneity. Indeed, we found that the  $\beta_2$ AR when bound to Nb60 and carazolol interconverts ( $860 \pm 530 \text{ s}^{-1}$ ) between S1 and S2 but is predominantly found (75–90%) in the S2 inactive state (Extended Data Figure 1d).

To further decipher how Nb60 induces a negative cooperative effect on agonist binding, we determined a  $3.2 \text{ \AA}$  X-ray crystal structure of a ternary complex comprised of  $\beta_2$ AR, Nb60, and the inverse agonist carazolol (Fig. 2d–f, Extended Data Figure 2, Extended Data Table 2). The complementary determining region 3 (CDR3) of Nb60 inserts into a similar  $\beta_2$ AR allosteric pocket as G-protein and Nb80, located between the cytoplasmic ends of TM3, TM4 and TM6 (Fig. 2d, e). We found that T102 and Y106 in Nb60 bridge an interaction between residues R131<sup>3.50</sup> and E268<sup>6.30</sup>. This interaction does not exist in the absence of Nb60 (PDB ID: 2RH1), indicating that Nb60 stabilizes an inactive conformation through interactions with the  $\beta_2$ AR ionic lock (Fig. 2e). However, this polar network appears “disengaged” compared to the fully closed ionic lock in the  $\beta_1$ -adrenergic receptor (PDB ID: 2YCW<sup>22</sup>) (Fig. 2e), thus supporting the <sup>19</sup>F-NMR data showing that Nb60 specifically stabilizes the S2 inactive state. The insertion of Nb60 F103 into a hydrophobic pocket in the  $\beta_2$ AR may also contribute to the affinity and/or negative allosteric properties of Nb60 (Extended Data Figure 2c). Confirming the importance of T102 and F103 for the  $\beta_2$ AR-Nb60 interaction, alanine mutations at these positions inhibited Nb60 binding to the  $\beta_2$ AR and the negative cooperative effects on ISO binding (Extended Data Figure 2e,f). Other than changes within the ionic lock, the overall structure of  $\beta_2$ AR bound to Nb60 is highly similar to the previously determined inactive  $\beta_2$ AR structure bound to carazolol alone (RMSD  $0.3 \text{ \AA}$  for the transmembrane domains and orthosteric binding pocket, Fig. 2f). Taken together, the pharmacological, biophysical, and crystallographic studies show that Nb60 exerts its negative allosteric effect on agonist binding by stabilizing the S2 inactive  $\beta_2$ AR conformation.

Our observation that ISO bound to the Nb80-stabilized active  $\beta_2$ AR with approximately 15,000-fold greater affinity than to the Nb60-stabilized inactive  $\beta_2$ AR (Fig. 1b and c) provides a measurement of the full allosteric power of an agonist to activate a GPCR. The large free energy difference ( $-24$  kJ/mol) between these states is likely important for GPCR function, allowing agonist-stimulated activity to be significantly higher than that of the basal activity. As simulated for a full agonist in Figure 3a, the overall affinity shift from inactive to active receptor (black arrow) is comprised of two components, the negative cooperative effects of Nb60 ( $\alpha$ Nb60, blue) and positive effects of Nb80 ( $\alpha$ Nb80, red). Given the complexities and limitations of using NMR and crystallography to gain mechanistic insights into ligand activation of a GPCR, we utilized a pharmacological approach to quantify  $\alpha$ Nb60 and  $\alpha$ Nb80 for 17  $\beta_2$ AR ligands of varying efficacy (Fig. 3b, Extended Data Figure 3).

We first identified a significant positive correlation ( $r = 0.8514$ ,  $p = 0.004$ ) between  $\alpha$ Nb80 values (i.e.,  $K_L/K_H$  ratios) and the relative intrinsic efficacies (i.e.,  $\tau$  ratios) of various ligands obtained from cellular G-protein assays (Extended Data Figure 4a–b). This finding provides additional support for the claim that Nb80 exerts allosteric effects that mimic those of a G protein. It also confirms our previous reports that ligand efficacy is not a product of modified downstream signaling events but is rather achieved at the level of ternary complex interactions, reflecting the allosteric interactions between different ligands and ‘transducers’<sup>12</sup>. Interestingly, we find no significant correlation between  $\alpha$ Nb60 and ligand efficacy, providing the first evidence that ligands perceive the Nb60 and Nb80 stabilized receptor states differently (Extended Data Figure 4c). Next we observed a significant negative correlation ( $r = 0.7417$ ,  $p = 0.0013$ ) between  $\alpha$ Nb60 and  $\alpha$ Nb80 values (Fig. 3c) across all ligands, suggesting these nanobodies stabilize functionally opposite conformations. However, the relationship between  $\alpha$ Nb60 and  $\alpha$ Nb80 was unexpectedly complex (Fig. 3b). For example, several full agonists exhibited comparable levels of positive (Nb80) and negative (Nb60) cooperativity (i.e., norepinephrine, epinephrine, and isoproterenol), while some partial agonists displayed surprisingly discrepant patterns (i.e., clenbuterol, salbutamol, and zinterol) (Fig. 3b). Importantly, for a subset of these ligands we confirmed that the allosteric effects of Nb80 are consistent with those elicited by the physiological transducer heterotrimeric Gs (Extended Data Figure 5a,b). Moreover, the surprisingly divergent, ligand-specific effects of Nb60 were also observed with another inactive state-stabilizing nanobody, A11 (Extended Data Figure 5c). Together, these data indicate that the ligand-specific effects of Nb80 and Nb60 are not nanobody-specific but rather reflect how ligands perceive specific receptor conformations.

We next tested two different allosteric models to try to explain how the different conformations stabilized by Nb60 and Nb80 can generate the observed cooperativities. First we tested whether the dynamics of receptor states can be sufficiently modeled as a simple interconversion between two allosteric conformations, despite biophysical evidence for multiple inactive and active receptor states. Accordingly we attempted to fit the experimentally observed  $\alpha$ Nb60 and  $\alpha$ Nb80 values for all ligands using the two-state model of receptor activation (Fig. 4a). In this simulation, the equilibrium constant  $J$  represents the distribution of inactive ( $R_{60}$ ) and active ( $R_{80}$ ) receptor states in the absence of ligand. The variable  $\beta$  describes the effect that each ligand has on the distribution of receptor states ( $J$ ),



with agonists displaying larger  $\beta$  values (i.e., they stabilize more  $R_{80}$  relative to  $R_{60}$ ). As shown in Figure 4a, the theoretical curve generated by varying  $\beta$  in the two-state model (dotted black line) failed to accurately predict the experimentally determined  $\alpha\text{Nb60}$  and  $\alpha\text{Nb80}$  values for 30% of ligands tested, consisting primarily of partial agonists (dotted red oval). A different equilibrium  $J$  constant would be required to explain the cooperativity of these ligands with the same two-state model. These findings argue that ligands must modulate more than these two states to control receptor activation.

Biophysical evidence supports the existence of at least three predominant receptor states; therefore we hypothesized that a three-state model (Fig. 4b) may better explain the experimentally observed  $\alpha\text{Nb60}$  and  $\alpha\text{Nb80}$  values. In this model, the equilibria of  $R_{80}$  ( $J_1$ ) and  $R_{60}$  ( $J_2$ ) can be regulated separately by ligands, described by the allosteric factors  $\beta_1$  and  $\beta_2$ , respectively. We found that the observed cooperativities for 12 ligands (Fig. 4b, class I, orange), which encompasses all the full agonists, can be predicted if these ligands primarily stabilize the active  $R_{80}$  state while having negligible effects on the inactive  $R_{60}$  state. The efficacy of these ligands is thus directly proportionally related to their effect on the  $R_{80}$  equilibrium ( $\beta_1$ ), such that highly efficacious ligands have a large  $\beta_1$  (i.e., epinephrine) while partial agonists have a lower  $\beta_1$  (i.e., clenbuterol). In contrast, the observed cooperativity of other partial agonists (classes II and III) could only be predicted by differentially modulating the  $R_{80}$  and  $R_{60}$  equilibria, suggesting these ligands regulate multiple receptor states to control receptor activation. For example, even though clenbuterol (CLEN, class I), zinterol (ZINT, class II), and procaterol (PROC, class III) are similar partial agonists (Extended Data Figure 4a), the mechanism by which they promote receptor activation varies based on their ability to differentially stabilize and destabilize the active ( $R_{80}$ ) and inactive ( $R_{60}$ ) states, respectively (Fig. 4b). Importantly, divergences in receptor activation mechanisms can only be uncovered by studying ligand effects at both the Nb60- and Nb80-stabilized  $\beta_2\text{AR}$  states. The inability to accurately predict efficacy (G-protein activation) based on ligand class supports the notion that molecular efficacy is a complex process that likely involves many more unresolved receptor states.

Our findings significantly reshape current understanding of GPCR activation. For almost 40 years, studies of these receptors have been guided by the understanding that they can exist in two forms, one of high affinity for agonists (active, coupled to G-protein) and one of low affinity (inactive, not coupled to G-protein), which are interconverted by the cooperative interaction of agonists and guanine nucleotides. We used conformationally sensitive nanobodies (Nb60, Nb80) to reveal that Nb60-bound  $\beta_2\text{AR}$  has affinity  $\sim 100$ -fold lower than the previously described low affinity inactive state, which is in fact an “average” of multiple, rapidly interconverting inactive and active states. The implication is that the full allosteric potential of the  $\beta_2\text{AR}$  is orders of magnitude greater than formerly appreciated. Moreover, binding cooperativity between ligands of varying efficacy and Nb60 and Nb80 could only be explained by models featuring multiple (at least three) receptor states, which are differentially stabilized and/or destabilized by various agonists. Thus these data demonstrate a previously unsuspected heterogeneity in the mechanisms by which different agonists stimulate biological responses. In view of the general conservation of GPCR activation mechanisms, and a report of an A2A adenosine receptor “Nb60-like” state, these findings will likely apply to many GPCRs. Given the primacy of GPCRs as therapeutic targets, these

new findings and concepts may also provide a basis for the design of drugs with potentially novel therapeutic properties.

## Methods

### $\beta_2$ AR reconstitution in HDL particles

Human  $\beta_2$ AR containing an amino-terminal FLAG epitope tag, carboxyl-terminal HIS-tag, and a N187E glycosylation mutation was expressed in Sf9 insect cells using the BestBac baculovirus system (Expression systems; Davis, CA). Cells were infected at a density of  $3 \times 10^6$  cells/mL and harvested 66 hours thereafter. Functional FLAG- $\beta_2$ AR was purified using FLAG-M1 antibody and alprenolol affinity chromatography as previously described<sup>23</sup>. FLAG- $\beta_2$ AR was reconstituted into HDL particles (nanodiscs) according to previously published methods<sup>24</sup>. In brief, FLAG- $\beta_2$ AR was incubated with a 50-fold molar excess of membrane scaffold protein 1 (MSP1) and 8 mM POPC:POPG (3:2 molar ratio) for 1 hour at 4°C. Detergent was removed via biobeads overnight at 4°C, and receptor-containing nanodiscs were isolated using FLAG-M1 chromatography and size exclusion chromatography.

### Nanobody and Gs purification

Nanobodies were generated and purified as previously described<sup>6</sup>. In brief, Nb60 and Nb80 clones were originally obtained from one llama (*Lama glama*) immunized with  $\beta_2$ AR (truncated at residue 365) reconstituted into liposomes bound to the high affinity agonist BI-167107. Nanobody coding sequences were amplified from isolated lymphocyte RNA and cloned into phage display vector. Conformationally selective nanobodies were isolated using a series of biopanning procedures targeted against native receptor bound to agonist. Nanobodies were grown in *E. coli* WK6 cells and purified from the periplasmic extract using nickel-agarose and resource S ion exchange chromatography. Heterotrimeric Gs protein was expressed in and purified from Sf9 insect cells using nickel-agarose and ion exchange chromatography as described previously<sup>25</sup>.

### Radioligand binding assays

Competition binding assays (250  $\mu$ L) contained 60 pM [<sup>125</sup>I]-CYP, a serial dilution of competitor, the indicated concentration of nanobody/Gs, and approximately 0.5 ng of  $\beta_2$ AR nanodiscs diluted in assay buffer (50 mM Tris-HCl pH 7.4, 12.5 mM MgCl<sub>2</sub>, 2 mM EDTA, 0.05% BSA, 1mM L-ascorbic acid). Total binding was determined in the absence of competitor; nonspecific binding was determined using 10  $\mu$ M propranolol. Following a 90 min incubation at room temperature, binding assays were terminated by rapid filtration onto GF/B glass-fiber filters treated with 0.3% PEI and washed with 8 mL of cold binding buffer using a harvester (Brandel, Gaithersburg, MD). Bound [<sup>125</sup>I] was quantified using a Packard Cobra Quantum gamma counter (Packard, San Diego, CA) and expressed as specific binding. For [<sup>3</sup>H]-ICI 118,551 binding, 10 ng of  $\beta_2$ AR nanodiscs were incubated with 0.3 nM radioligand and varying concentrations of nanobody and were harvested as described above. [<sup>125</sup>I]-CYP affinity was determined using saturation binding (Extended Data Table 1). All binding data represent a minimum of three independent experiments with deviation represented as standard error.



### Isothermal Titration Calorimetry (ITC)

ITC experiments were carried out using the MicroCal iTC200 system.  $\beta_2$ AR and Nb60, purified as described above, were both dialyzed against a buffer consisting of 20 mM HEPES pH 7.5, 100 mM NaCl, 0.01% Lauryl Maltose Neopentyl Glycol (MNG), and 0.001% cholesteryl hemisuccinate (CHS). Protein concentrations were determined by measurement of the absorbance at 280 nm, using molar extinction coefficient per cm parameters of each protein ( $\epsilon$  for  $\beta_2$ AR: 66350  $\text{cm}^{-1}$  and Nb60: 21430  $\text{cm}^{-1}$ ). Nb60 at 100  $\mu\text{M}$  concentration (40  $\mu\text{L}$ ) was loaded into the syringe and titrated into the 200  $\mu\text{L}$  sample cell containing  $\beta_2$ AR (10  $\mu\text{M}$ ) in absence or presence of 200  $\mu\text{M}$  ISO. Titrations were performed at 25  $^\circ\text{C}$  using an initial injection of 0.5  $\mu\text{L}$ , followed by 2.3  $\mu\text{L}$  injections (1 s duration, 300 s spacing, and 5 s filter period). Reference power was set to 10  $\mu\text{cal s}^{-1}$  and stirring speed to 750 r.p.m. Reference titrations were obtained by injecting Nb60 alone or Nb60 with agonist (ISO) into sample cells containing buffer alone. To obtain the stoichiometry ( $N$ ) and association constant ( $K_A$ ) of the interaction, the raw data were baseline corrected, peak area integrated, and fitted to a one-site non-linear least squares fit model using the Origin@7 software program. Binding experiments were performed at least twice to calculate standard deviations.

### Enzyme-linked immunosorbent assay (ELISA) for determining Nb $K_T$

The affinity of each nanobody for the unliganded  $\beta_2$ AR ( $K_T$ ) was required for TCM data analysis. Briefly, 50 ng of carboxypeptidase-treated (to remove His<sub>6</sub> tag), biotinylated  $\beta_2$ AR nanodiscs were immobilized per well of a 96-well SigmaScreen Streptavidin plate in binding buffer (20 mM HEPES pH 7.4, 100 mM NaCl, 2 mM EDTA). Following a 3 hr incubation at RT, plates were washed four times with binding buffer and incubated with serial dilutions of nanobody in binding buffer with 0.1% milk for 2 hr at RT. Plates were quickly washed three times with binding buffer and then incubated with polyclonal anti-His HRP-conjugated antibody (1:5000, Abcam) in binding buffer with 0.1% milk for 1 hr at RT. Plates were quickly washed three times with binding buffer and bound nanobody was detected colorimetrically (OD<sub>450nm</sub>) on a NovoStar plate reader (BMG Labtech) using TMB Ultra 1-step substrate as described by the manufacturer (Pierce).

### Crystallization of $\beta_2$ AR-carazolol-Nb60 complex

For crystallography trials, we utilized a previously described fusion protein of human  $\beta_2$ AR with an amino-terminal T4 lysozyme (T4L) fusion and a truncated intracellular loop three<sup>26</sup>. The T4L- $\beta_2$ AR fusion protein was expressed and purified as described above. Purified receptor was incubated with 5- and 2-fold molar excess of carazolol and Nb60, respectively. The  $\beta_2$ AR-carazolol-Nb60 complex was incubated overnight at 4 $^\circ\text{C}$  and further purified by size exclusion chromatography over a Sephadex S200 column in a buffer comprised of 20 mM HEPES pH 7.5, 100 mM NaCl, 0.01% MNG, and 0.001% CHS. The purified complex was concentrated to 37.5 mg/ml and flash frozen in liquid nitrogen for crystallization trials. We utilized the *in meso* crystallization method with a 10:1 (w/w) mix of 7.7 monoacylglycerol (MAG 7.7) and cholesterol as the host lipid (Avanti Polar Lipids). Samples were thawed and reconstituted with the host lipid at a 1:1 ratio with the two-syringe mixing method until a clear phase was achieved. The resulting lipidic cubic phase was

dispensed in 35 nL drops onto glass sandwich plates using a GryphonLCP robot (Art Robbins Instruments). Crystals grew in a precipitant solution comprised of 100 mM HEPES pH 7.5, 20 mM EDTA, and 19–23% PEG300. Although crystals appeared in 2–3 days, the best diffraction was obtained from crystals that grew over 30 days. Crystals were harvested with mesh loops (Mitegen) and flash frozen in liquid nitrogen.

### Data collection and refinement

X-ray diffraction was collected at the Advanced Photon Source GM/CA beamline 23ID-B. As with previous *in meso* crystallography of GPCRs, crystals suffered considerable radiation damage during data collection. Typically, 20–60 degree wedges of data were collected using a 20  $\mu\text{m}$  beam. The resulting diffraction data from 10 crystals were processed in HKL2000<sup>27</sup>. The structure of the  $\beta_2\text{AR}$ -carazolol-Nb60 complex was solved by molecular replacement using carazolol-bound  $\beta_2\text{AR}$  with the T4 lysozyme removed (PDB ID: 2RH1) and a structure of Nb60 solved to 1.8 $\text{\AA}$  as search models in Phaser<sup>28</sup>. The model was refined iteratively in Phenix<sup>29</sup> with manual rebuilding in Coot<sup>30</sup> with and without averaging of non-crystallographic symmetry. The quality of the final model was assessed using MolProbity<sup>31</sup> and refinement statistics are presented in Extended Data Table 2. Figures were prepared using PyMOL (Schrödinger). The RMSD analysis for the orthosteric binding pocket was performed in PyMOL by measuring residues within 4 $\text{\AA}$  of the ligand carazolol between  $\beta_2\text{AR}$ -Nb60-Cz and 2RH1.

### <sup>19</sup>F-NMR of $\beta_2\text{AR}$

<sup>19</sup>F-fluorine NMR studies were conducted as previously described<sup>5</sup>. Briefly, full-length  $\beta_2\text{AR}$  with four cysteine mutations (C77V, C327S, C378A, and C406A) was expressed in Sf9 cells, extracted using dodecylmaltoside, and purified initially by M1 FLAG affinity chromatography. The receptor sample was subsequently labeled with a bromotrifluoroacetanilide probe at a 5-fold stoichiometric excess and purified by alprenolol-sepharose and M1 affinity chromatography. As done for previous <sup>19</sup>F-NMR experiments, the detergent was gradually exchanged to 0.01% lauryl maltose neopentyl glycol (MNG, Anatrace). The final receptor sample was concentrated to 200  $\mu\text{M}$  and a 2.5-fold molar excess of carazolol was added prior to acquisition of NMR data. After acquisition of signal for the  $\beta_2\text{AR}$ -carazolol complex, Nb60 was added to a 2.5-fold molar excess, and <sup>19</sup>F-NMR spectra were obtained for the  $\beta_2\text{AR}$ -carazolol-Nb60 complex. NMR studies were performed at 25 $^\circ\text{C}$  on a 600 MHz Varian Inova spectrometer equipped with a cryogenic probe capable of <sup>19</sup>F-NMR (600 MHz). All spectral processing was performed using Mnova 9.0.0 (Mestrelab Research). Additional information on data processing and line shape simulations are described in detail elsewhere<sup>5</sup>. <sup>19</sup>F CPMG relaxation data were recorded by applying CPMG frequencies ranging from 500 to 5000 Hz at 600 MHz with a constant time of 2 ms. CPMG profiles were fitted to a two state model with Chemex as described elsewhere<sup>32</sup>. The <sup>19</sup>F  $\pi/2$  pulse width was 19  $\mu\text{s}$ .

### Fitting of binding curves with the Ternary Complex Model

The allosteric effect of nanobodies on the binding of receptor ligands is quantified by the cooperativity factor  $\alpha$ . Its magnitude is given by a ratio of dissociation constants (i.e.,  $K_L/K_H$  for Nb80 and  $K_L/K_{VL}$  for Nb60) determined from the comparison of how each ligand binds

to  $\beta_2$ AR in the absence of versus the saturating presence of each Nb (Extended Data Figure 3). However, under conditions in which the nanobody concentration is sub-saturating or the radiotracer  $\alpha$  is not exactly 1, experimental  $K_d$  ratios may underestimate the size of the cooperativity factor. To improve measurements of Nb/ligand  $\alpha$  values, we fitted the binding curves with a mathematical function derived from TCM. This entails solving the following nonlinear system of equations that yield the concentration of free species for a binding reaction consisting of one receptor ( $R$ ), one Nb ( $N$ ) and  $n$  ligands ( $L_j$ ) at equilibrium:


$$[R]_f = [R]_t \cdot \left\{ 1 + M[N]_f + \sum_{i=1}^n K_i [L_i]_f (1 + \alpha_i M[N]_f) \right\}^{-1}$$

$$[N]_f = [N]_t \cdot \left\{ 1 + M[R]_f \left( 1 + \sum_{i=1}^n \alpha_i K_i [L_i]_f \right) \right\}^{-1}$$

$$[L_i]_f = [L_i]_t \cdot \left\{ 1 + K_i [R]_f (1 + \alpha_i M[N]_f) \right\}^{-1}$$

where subscripts  $f$  and  $t$  indicate respectively free and total concentrations and the equilibrium binding constants of ligands ( $K$ ) and nanobody ( $M$ ) are defined as in supplemental (analysis of binding cooperativity). Exact numerical solutions were obtained using a globally convergent iterative algorithm<sup>33</sup>, which was coded as add-in function for MS-Excel<sup>34</sup>. The built-in optimizer “Solver” was used to minimize the sum of squares difference between predicted and experimental data (choosing the Newton search option and setting convergence threshold at  $10^{-12}$ ). Sets of 3 curves representing bound radiotracer as a function of increasing concentrations of unlabeled ligand, obtained in the absence and presence of Nb80 or Nb60, were fitted simultaneously. Known parameters are the  $M$  of each Nb (Extended Data Figure 6), the  $K$  and  $\alpha$  value of [<sup>125</sup>I]-CYP (Extended Data Figure 1). Unknown fitted parameters are: non-specific tracer binding, receptor concentration and  $K$  value of the competing ligand (both shared across the 3 curves), and the individual  $\alpha$ Nb80,  $\alpha$ Nb60 values for each ligand/Nb pair. For data measured in the presence of Gs (the  $M$  value of which was not available), all ligands curves were fitted globally and constrained to share a common best-fitting  $M$ . This fitted value was close to that experimentally measured for Nb80.


Extended Data



**Extended Data Figure 1. Characterization of Nb60 interaction with  $\beta_2$ AR**


Competition equilibrium binding studies using [ $^{125}$ I]-cyanopindolol (CYP), the cold competitor agonist isoproterenol (ISO),  $\beta_2$ AR in HDL particles, and the indicated concentration of (a) Nb80, (b) Gs, or (c) Nb60. Dotted vertical line represents logIC50 in absence of modulator, and the change in ligand affinity is depicted with colored arrows. (d)  $^{19}$ F-NMR CPMG relaxation dispersion experiment with  $\beta_2$ AR-Nb60-Carazolol (Cz).  $K_{ex}$  – Exchange Rate. (e) Competition equilibrium binding studies using [ $^{125}$ I]-CYP, the non-labeled competitor agonist ISO,  $\beta_2$ AR in HDL-particles, and 1  $\mu$ M Nb60 WT or T102A/F103A. (f) ELISA depicting capture of  $\beta_2$ AR by Nb60 or the T102A/F103A variant. Inset: Coomassie stain of nanobody input. Radioligand binding and ELISA experiments were performed at least three times with deviation shown as standard error.





**Extended Data Figure 2. Characterization of  $\beta_2$ AR-Nb60-carazolol crystals**

(a) Monodispersity of T4L- $\beta_2$ AR-Nb60-carazolol ( $\beta_2$ AR-Nb60-Cz) complex as assessed by size exclusion chromatography. Inset: Coomassie stain illustrating presence of  $\beta_2$ AR and Nb60 in fractions combined for crystallography. (b) Representative picture of  $\beta_2$ AR-Nb60-Cz lipidic cubic phase (LCP) crystals. (c) Insertion of F103 (green) from Nb60 CDR3 (purple) into hydrophobic  $\beta_2$ AR pocket, nitrogen and oxygen shown as blue and red shaded surfaces, respectively. (d) Example of  $\beta_2$ AR-Nb60-Cz crystal lattice. (e) Electron density 2FO-FC map (Sigma: 1) of carazolol binding pocket (top panels) Nb60 CDR3 binding pocket (bottom panels) within  $\beta_2$ AR.



**Extended Data Figure 3. Differential effects of Nb60 and Nb80 on the affinity of 12 different  $\beta_2$ AR ligands**


Competition equilibrium binding studies using [ $^{125}$ I]-cyanopindolol (CYP), the indicated non-labeled competitor,  $\beta_2$ AR in HDL-particles, and 1  $\mu$ M of Nb60 or Nb80. Data represent at least three independent experiments with deviation depicted as standard error.




**a.**

|                | cAMP (GloSensor) |           | Ligand Affinity |           | Log Tau |           | Log $\alpha$ Nb80 |           | Log $\alpha$ Nb60 |           |
|----------------|------------------|-----------|-----------------|-----------|---------|-----------|-------------------|-----------|-------------------|-----------|
|                | LogEC50          | Std. Err. | Ki              | Std. Err. | Mean    | Std. Err. | Mean              | Std. Err. | Mean              | Std. Err. |
| Isoproterenol  | -9.622           | 0.046     | -6.838          | 0.013     | 2.16    | 0.226     | 2.93              | 0.112     | -2.88             | 0.300     |
| Formoterol     | -9.596           | 0.070     | -8.068          | 0.024     | 1.12    | 0.216     | 1.72              | 0.328     | -2.14             | 0.391     |
| Salbutamol     | -7.746           | 0.077     | -5.868          | 0.023     | 2.23    | 0.186     | 2.92              | 0.257     | -0.59             | 0.073     |
| Salmeterol     | -7.989           | 0.070     | -8.666          | 0.021     | 0.57    | 0.115     | 1.82              | 0.198     | -0.67             | 0.137     |
| HBI            | -9.579           | 0.097     | -7.076          | 0.039     | 1.96    | 0.218     | 2.16              | 0.358     | -2.73             | 0.005     |
| Epinephrine    | -8.885           | 0.130     | -5.950          | 0.035     | 2.70    | 0.191     | 3.16              | 0.401     | -3.40             | 1.010     |
| Norepinephrine | -6.941           | 0.087     | -4.844          | 0.039     | 1.93    | 0.165     | 3.33              | 0.095     | -3.37             | 0.614     |
| Clenbuterol    | -8.499           | 0.075     | -7.508          | 0.042     | 1.82    | 0.173     | 2.41              | 0.048     | -0.07             | 0.093     |
| Fenoterol      | -9.223           | 0.051     | -6.494          | 0.036     | 2.34    | 0.200     | 2.96              | 0.091     | -1.46             | 0.270     |
| Isoetharine    | -8.646           | 0.070     | -5.856          | 0.051     | 2.33    | 0.193     | 3.01              | 0.078     | -3.38             | 0.606     |
| Zinterol       | -8.949           | 0.079     | -7.896          | 0.029     | 1.47    | 0.164     | 2.09              | 0.229     | -0.63             | 0.114     |
| Procaterol     | -9.188           | 0.108     | -7.468          | 0.046     | 1.12    | 0.184     | 1.39              | 0.052     | -1.86             | 0.204     |

**b.**




**c.**




**Extended Data Figure 4. Agonist induced G-protein activation *in cellulo* correlates with the magnitude of affinity change mediated by Nb80 *in vitro***


(a) Table representing cell signaling and ligand affinity data. Ligand-dependent G-protein activation was quantified by measuring cAMP levels (GloSensor, Promega) from HEK293 cells over-expressing  $\beta_2$ AR. Ligand affinity was measured in membranes prepared from the same cells as above using competition binding assays with [ $^{125}$ I]-CYP. Ligand efficacy (log Tau) was calculated as previously described<sup>36</sup>. See methods and supplemental material for cooperativity ( $\alpha$ ) determination. Correlation plot of logTau and  $\alpha$ Nb80 (b) or  $\alpha$ Nb60 (c). All data represent at least three independent experiments with deviation shown as standard error.



**Extended Data Figure 5. Positive correlation between allosteric properties of Nb80 and Gs**  
**(a)** Equilibrium binding studies using HDL-β<sub>2</sub>AR, [<sup>125</sup>I]-cyanopindolol, the indicated unlabeled competitor, and 100 nM purified heterotrimeric Gs-protein. **(b)** Correlation plot of cooperativity values (α) for Nb80 and Gs. **(c)** Sequence alignment of Nb60 and NbA11. Radioligand competition binding studies with Nb80, Nb60 or NbA11, [<sup>125</sup>I]-cyanopindolol, the unlabeled competitor isoproterenol or clenbuterol, and HDL-β<sub>2</sub>AR. All data represent at least three independent experiments with deviation shown as standard error.




**Extended Data Figure 6. Affinity determination for Nb60 and Nb80 for unliganded  $\beta_2$ AR**  
 ELISA assay detecting capture of increasing concentrations of Nb60 or Nb80 by immobilized HDL- $\beta_2$ AR in the absence of ligand. All data represent at least three independent experiments with deviation shown as standard error.



**Extended Data Figure 7. Theoretical framework illustrating the two views of allostery**  
**(a)** Nested reaction schemes at equilibrium indicating the correspondence (*arrowed light-blue shades*) between binding site cooperativity (TCM in outer box) and changes of allosteric conformations (inner cubes). Arrows stand for reversible equilibrium interactions.  
**(b)** Change of the macroscopic dissociation constant ( $1/K$ ) of a ligand L (shifting the

equilibrium towards  $r_1$ ) induced by increasing the concentrations of nine different N-ligands with diverse allosteric effects ( $\gamma_1, \gamma_2$ ) on receptor states. Simulations were made using a 3-state model based on the parameter values listed on the right side of the plot (curves on the left side are color coded in red/blue tones according to right-side boxes). The change in  $K$  (i.e. log difference between presence and absence of N) is calculated from eq. 1 in SI (Analysis of nanobody allostery).



**Extended Data Figure 8. Comparison of experimental and theoretical cooperativities predicted according to a 2-state (a–d) or 3-state (e, f) allosteric models**

(See also SI, “Analysis of nanobody allostery.”) **(a–d d)** Theoretical  $\log \alpha$  values were computed according to a 2-state model for a series of hypothetical ligands (L) ( $\log \beta_1$  range:  $-4/8$ ) and a positive (PAN,  $\log \gamma_1 \gg 0$ ) or negative (NAN,  $\log \gamma_1 \ll 0$ ) nanobody. **(a)** Observed data overlaid on values simulated at  $J_1 = 8.9 \times 10^{-4}$  in histogram form (with experimental bars drawn on the closest theoretical  $\log \beta_1$  bin value), or superimposed **(b)** on the  $\log \alpha_{\text{NAN}}$  vs.  $\log \alpha_{\text{PAN}}$  relationships predicted for different  $J_1$  values. The same data are replotted as separate graphs for lower  $J_1$  **(c)** and larger  $J_1$  **(d)** values, to show the sigmoid relationships existing between macroscopic  $\log \alpha$ 's and  $\log \beta_1$ . **(e, f)** Simulations made according to the 3-state allosteric model: **(e)** predicted (lines) and observed (circles)  $\log \alpha$  values plotted as functions of  $\log (\beta_1/\beta_2)$ . Three groups of ligands (I to III, defined by the table of  $a_0$  and  $m$  parameters) produce increasingly stronger reductions of  $r_2$  equilibrium. **(f)** Same data plotted as  $\log \alpha_{\text{Nb60}}$  vs.  $\log \alpha_{\text{Nb80}}$  relationships (see fig. 4, main paper). All  $\alpha$  values derived from at least three independent radioligand binding experiments with deviation depicted as standard error.

**Extended Data Table 1**

Effect of Nb60 and Nb80 on [ $^{125}\text{I}$ ]-Cyanopindolol affinity.

|         | [ $^{125}\text{I}$ ]-Cyanopindolol Affinity |      | Kd Ratio   |      |
|---------|---|------|------------|------|
|         | Kd (pM)                                     | SEM  | Control/Nb | SEM  |
| Control | 737.3                                       | 92.9 | ----       | ---- |
| Nb80    | 315.6                                       | 62.4 | 2.5        | 0.35 |
| Nb60    | 663.0                                       | 17.7 | 1.1        | 0.12 |

**Extended Data Table 2**

Data collection and refinement statistics (molecular replacement).

| $\beta_2\text{AR-Carazolol-Nb60}^d$   |                       |
|---------------------------------------|-----------------------|
| <b>Data collection<sup>b</sup></b>    |                       |
| Space group                           | $P2_12_12_1$          |
| Cell dimensions                       |                       |
| $a, b, c$ (Å)                         | 43.9, 164.5, 218.8    |
| $\alpha, \beta, \gamma$ (°)           | 90.0, 90.0, 90.0      |
| Resolution (Å)                        | 32.9–3.2 (3.30–3.20)  |
| $R_{\text{merge}}$ (%)                | 17.5 (89.6)           |
| $\langle I/\sigma I \rangle$          | 5.3 (1.5)             |
| $\text{CC}_{1/2}$ (%)                 | 98.6 (82.4)           |
| Completeness (%)                      | 98.6 (95.5)           |
| Redundancy                            | 5.5 (4.6)             |
| <b>Refinement</b>                     |                       |
| Resolution (Å)                        | 32.9–3.2 (3.30–3.20)  |
| Number of reflections                 | 26,778                |
| $R_{\text{work}}/R_{\text{free}}$ (%) | 24.7/29.0 (38.3/43.9) |



| $\beta_2$ AR-Carazolol-Nb60 <sup>d</sup> |        |
|--|--------|
| Number of atoms                          |        |
| Protein                                  | 7,703  |
| Ligand (Carazolol)                       | 44     |
| Solvent (lipid, water, other)            | 56     |
| B-factors (Å <sup>2</sup> )              |        |
| Protein                                  | 129.81 |
| Ligand (Carazolol)                       | 116.36 |
| Solvent (lipid, water, other)            | 157.51 |
| R.M.S. deviation from ideality           |        |
| Bond lengths (Å)                         | 0.003  |
| Bond angles (°)                          | 0.429  |
| Ramachandran statistics <sup>c</sup> (%) |        |
| Favored                                  | 96.8   |
| Allowed                                  | 3.2    |
| Outliers                                 | 0      |

<sup>a</sup>Diffraction data from 10 crystals were merged into a complete data set.

<sup>b</sup>Highest resolution shell statistics are shown in parentheses.

<sup>c</sup>As calculated by Molprobit.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We thank Darrell Capel and Xinrong Jiang for technical assistance. Administrative and secretarial support was provided by Victoria Ronk, Katherine Harley, Donna Addison and Quivetta Lennon. We acknowledge support from the National Institute of Health Grants NS028471 (B.K.K.), T32HL007101 (D.P.S, L.M.W), HL16037 and HL70631 (R.J.L), from the Stanford Medical Scientist Training Program and the American Heart Association (A.M.), Italian Ministry of Health, grant RF-2011-02351158 (T.C.), and from the Mathers Foundation (B.K.K. and W.I.W.). R.J.L. is an investigator with the Howard Hughes Medical Institute.

## References

1. Khsai AW, et al. Multiple ligand-specific conformations of the beta2-adrenergic receptor. *Nat Chem Biol.* 2011; 7:692–700. [PubMed: 21857662]
2. Liu JJ, Horst R, Katritch V, Stevens RC, Wuthrich K. Biased signaling pathways in beta2-adrenergic receptor characterized by 19F-NMR. *Science.* 2012; 335:1106–1110. [PubMed: 22267580]
3. Kofuku Y, et al. Efficacy of the beta(2)-adrenergic receptor is determined by conformational equilibrium in the transmembrane region. *Nature communications.* 2012; 3:1045.
4. Nygaard R, et al. The dynamic process of beta(2)-adrenergic receptor activation. *Cell.* 2013; 152:532–542. [PubMed: 23374348]
5. Manglik A, et al. Structural Insights into the Dynamic Process of beta2-Adrenergic Receptor Signaling. *Cell.* 2015; 161:1101–1111. [PubMed: 25981665]
6. Rasmussen SG, et al. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. *Nature.* 2011; 469:175–180. [PubMed: 21228869]
7. Staus DP, et al. Regulation of beta2-adrenergic receptor function by conformationally selective single-domain intrabodies. *Molecular pharmacology.* 2014; 85:472–481. [PubMed: 24319111]




8. Colquhoun D. The quantitative analysis of drug-receptor interactions: a short history. *Trends in pharmacological sciences*. 2006; 27:149–157. [PubMed: 16483674]
9. Onaran HO, Costa T. Allosteric coupling and conformational fluctuations in proteins. *Current protein & peptide science*. 2009; 10:110–115. [PubMed: 19355978]
10. Colquhoun D. Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. *British journal of pharmacology*. 1998; 125:924–947. [PubMed: 9846630]
11. De Lean A, Stadel JM, Lefkowitz RJ. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. *The Journal of biological chemistry*. 1980; 255:7108–7117. [PubMed: 6248546]
12. Strachan RT, et al. Divergent transducer-specific molecular efficacies generate biased agonism at a G protein-coupled receptor (GPCR). *The Journal of biological chemistry*. 2014; 289:14211–14224. [PubMed: 24668815]
13. Wreggett KA, De Lean A. The ternary complex model. Its properties and application to ligand interactions with the D2-dopamine receptor of the anterior pituitary gland. *Molecular pharmacology*. 1984; 26:214–227. [PubMed: 6237254]
14. Ehlert FJ. The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. *Molecular pharmacology*. 1985; 28:410–421. [PubMed: 4058422]
15. Samama P, Cotecchia S, Costa T, Lefkowitz RJ. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. *The Journal of biological chemistry*. 1993; 268:4625–4636. [PubMed: 8095262]
16. Onaran HO, Rajagopal S, Costa T. What is biased efficacy? Defining the relationship between intrinsic efficacy and free energy coupling. *Trends in pharmacological sciences*. 2014; 35:639–647. [PubMed: 25448316]
17. Hino T, et al. G-protein-coupled receptor inactivation by an allosteric inverse-agonist antibody. *Nature*. 2012; 482:237–240. [PubMed: 22286059]
18. Dror RO, et al. Identification of two distinct inactive conformations of the beta2-adrenergic receptor reconciles structural and biochemical observations. *Proceedings of the National Academy of Sciences of the United States of America*. 2009; 106:4689–4694. [PubMed: 19258456]
19. Ballesteros JAWH. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein coupled receptors. *Meth. Neurosci*. 1995; 25:366–428.
20. Ballesteros JA, et al. Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. *The Journal of biological chemistry*. 2001; 276:29171–29177. [PubMed: 11375997]
21. S Meiboom DG. Modified Spin-Echo Method for Measuring Nuclear Relaxation Times. *Rev. Sci. Instrum*. 1958; 29:688–691.
22. Moukhametzanov R, et al. Two distinct conformations of helix 6 observed in antagonist-bound structures of a beta1-adrenergic receptor. *Proceedings of the National Academy of Sciences of the United States of America*. 2011; 108:8228–8232. [PubMed: 21540331]


## References for Methods section

23. Kobilka BK. Amino and carboxyl terminal modifications to facilitate the production and purification of a G protein-coupled receptor. *Analytical biochemistry*. 1995; 231:269–271. [PubMed: 8678314]
24. Whorton MR, et al. A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. *Proceedings of the National Academy of Sciences of the United States of America*. 2007; 104:7682–7687. [PubMed: 17452637]
25. Rasmussen SG, et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. *Nature*. 2011; 477:549–555. [PubMed: 21772288]
26. Ring AM, et al. Adrenaline-activated structure of beta2-adrenoceptor stabilized by an engineered nanobody. *Nature*. 2013; 502:575–579. [PubMed: 24056936]


27. Otwinowski, ZMW. Methods in Enzymology. Carter Charles, W., editor. Vol. 276. Academic Press; 1997. p. 307-326.
28. McCoy AJ, et al. Phaser crystallographic software. Journal of applied crystallography. 2007; 40:658–674. [PubMed: 19461840]
29. Adams PD, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta crystallographica. Section D, Biological crystallography. 2010; 66:213–221. [PubMed: 20124702]
30. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta crystallographica. Section D, Biological crystallography. 2004; 60:2126–2132. [PubMed: 15572765]
31. Chen VB, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta crystallographica. Section D, Biological crystallography. 2010; 66:12–21. [PubMed: 20057044]
32. Shi L, Kay LE. Tracing an allosteric pathway regulating the activity of the HslV protease. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111:2140–2145. [PubMed: 24469799]
33. Pradines JR, Hasty J, Pakdaman K. Complex ligand-protein systems: a globally convergent iterative method for the  $n \times m$  case. Journal of mathematical biology. 2001; 43:313–324. [PubMed: 12120871]
34. Vezzi V, et al. Ligands raise the constraint that limits constitutive activation in G protein-coupled opioid receptors. The Journal of biological chemistry. 2013; 288:23964–23978. [PubMed: 23836900]
35. Mashalidis EH, Sledz P, Lang S, Abell C. A three-stage biophysical screening cascade for fragment-based drug discovery. Nature protocols. 2013; 8:2309–2324. [PubMed: 24157549]
36. Rajagopal S, et al. Quantifying ligand bias at seven-transmembrane receptors. Molecular pharmacology. 2011; 80:367–377. [PubMed: 21610196]



**Figure 1. Allosteric nanobodies have opposing effects on agonist affinity for the  $\beta_2$ AR**  
**(a)** Schematic of the ternary complex model (TCM). Ligand (L) affinity to receptor (R) increases in the presence of transducer (T), this allosteric linkage is denoted by dashed line with arrows. **(b)** Compared to the absence of modulator, Nb60 decreases ISO affinity (negative cooperativity) and Nb80/Gs increases affinity (positive cooperativity) as assessed by radioligand competition assays using  $\beta_2$ AR HDL-particles. **(c)** The effects of Nb60 and Nb80/Gs on ISO affinity are saturable functions of their concentration. The affinity of Nb60 for unliganded  $\beta_2$ AR **(d)**, represented by a tight isotherm sigmoidal binding curve<sup>35</sup>, is reduced in the presence of ISO **(e)** as determined by isothermal titration calorimetry. **(f)** Nb60 dose dependently increases and Nb80 decreases the binding of the radiolabeled antagonist [<sup>3</sup>H]-ICI-118,551 to the  $\beta_2$ AR. All radioligand binding studies represent a minimum of three independent experiments with deviation shown as standard error.




**Figure 2. Nb60 stabilizes the S2 inactive state by coordinating the  $\beta_2$ AR ionic lock**  
 Cartoon depicting a side (a) or cytoplasmic (b) view of the  $\beta_2$ AR transmembranes (TM). Conversion from the two inactive states (S1 and S2) to the active S4 state requires both agonist and transducer (i.e. G-protein) binding and is represented by a 14Å outward movement of TM6. (c)  $^{19}\text{F}$ -NMR spectroscopy of the  $\beta_2$ AR with the antagonist carazolol (Cz) +/- Nb60. (d) The 3.2Å structure of the  $\beta_2$ AR bound to carazolol and Nb60 ( $\beta_2$ AR-Cz-Nb60). (e) Coordination of  $\beta_2$ AR ionic lock (R131 and E238) by Nb60 CDR3 residues T102 and Y106. For comparison, a disengaged and fully formed ionic lock are shown by the  $\beta_2$ AR-Cz (PDB ID: 2RH1) and  $\beta_1$ AR-Cz (PDB ID: 2YCZ), respectively. Hydrogen bonds shown as black dotted lines. (f) Overlay of  $\beta_2$ AR-Cz and  $\beta_2$ AR-Cz-Nb60 structures.



**Figure 3. Nb60 and Nb80 have varying effects on the affinity of different  $\beta_2$ AR ligands**  
**(a)** Schematic depicting the use of equilibrium radioligand binding studies to quantify the cooperativity ( $\alpha$ ) between Nb60 or Nb80 binding and ligand affinity (see methods and supplemental information). **(b)** Cooperativity values for Nb60 ( $\alpha$ Nb60) and Nb80 ( $\alpha$ Nb80) for  $\beta_2$ AR ligands with varying efficacies. Ligands are ordered by magnitude of  $\alpha$ Nb80. **(c)** Correlation plot of  $\alpha$ Nb60 and  $\alpha$ Nb80; regression shown as solid red line with 95% confidence interval (dotted red line). All  $\alpha$  values derived from at least three independent radioligand binding experiments with deviation depicted as standard error.





**Figure 4.  $\beta_2$ AR agonists differentially stabilize receptor states to regulate receptor activation** Illustration of a two- (a) or three-state (b) model of receptor activation describing the effect of  $\beta_2$ AR ligands on receptor conformations stabilized by Nb60 ( $R_{60}$ ) or Nb80 ( $R_{80}$ ). The equilibrium ( $J$ ) between receptor states can be influenced by ligand binding through the allosteric factor  $\beta$ . The theoretical cooperativity ( $\alpha$ ) between nanobody and ligand binding derived from the 2-state model (dashed black line) fails to predict the observed  $\alpha$  values for a subset of ligands (dashed red oval). However, the observed cooperativity values can be accurately predicted using an allosteric model in which ligands can differentially modulate three independent receptor states (3-state). Certain ligands (orange) primarily stabilize the active  $R_{80}$  state, whereas others (purple, green) can stabilize  $R_{80}$  but simultaneously destabilize the inactive  $R_{60}$  state. All  $\alpha$  values derived from at least three independent radioligand binding experiments with deviation depicted as standard error.